{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=44", "query": { "condition": "Melanoma Neoplasms", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 2204, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T15:37:30.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00289016", "title": "A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioVex Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-12", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-12-18", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Robbinsdale", "state": "Minnesota" }, { "city": "Montclair", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289016" }, { "nct_id": "NCT00436410", "title": "Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adrenocortical Carcinoma", "Breast Cancer", "Colorectal Cancer", "Gastrointestinal Cancer", "Kidney Cancer", "Liver Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Sarcoma" ], "interventions": [ { "name": "colloidal gold-bound tumor necrosis factor", "type": "BIOLOGICAL" }, { "name": "electron microscopy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2006-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-05-02", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436410" }, { "nct_id": "NCT03825913", "title": "3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Wellness Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-11-06", "completion_date": "2020-02-21", "has_results": false, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03825913" }, { "nct_id": "NCT03864042", "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Melanoma" ], "interventions": [ { "name": "losartan", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "rosuvastatin", "type": "DRUG" }, { "name": "bupropion immediate release (IR)", "type": "DRUG" }, { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "modafinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-01-02", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Hopkins", "state": "Minnesota" }, { "city": "Maple Grove", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03864042" }, { "nct_id": "NCT01127594", "title": "Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Douglas Tyler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2010-07", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 3, "location_summary": "Tampa, Florida • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01127594" }, { "nct_id": "NCT05736523", "title": "Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-09-23", "completion_date": "2025-06", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 2, "location_summary": "Murray, Utah • Salt Lake City, Utah", "locations": [ { "city": "Murray", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736523" }, { "nct_id": "NCT01967823", "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Meningioma", "Breast Cancer", "Non-Small Cell Lung Cancer", "Hepatocellular Cancer" ], "interventions": [ { "name": "Anti-NY ESO-1 mTCR PBL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 11, "start_date": "2013-10-24", "completion_date": "2020-04-06", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967823" }, { "nct_id": "NCT02068586", "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Iris Melanoma", "Stage I Intraocular Melanoma", "Stage IIA Intraocular Melanoma", "Stage IIB Intraocular Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIC Intraocular Melanoma", "Stage I Uveal Melanoma AJCC V7", "Stage II Uveal Melanoma AJCC V7", "Stage III Uveal Melanoma AJCC V7" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Sunitinib Malate + Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-11-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02068586" }, { "nct_id": "NCT03504488", "title": "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Melanoma", "Head and Neck Cancer" ], "interventions": [ { "name": "CAB-ROR2-ADC", "type": "BIOLOGICAL" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2018-06-27", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504488" }, { "nct_id": "NCT04759781", "title": "MElanoma Research Lymph Node Prediction Implementation National_001", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "SkylineDx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1820, "start_date": "2021-08-25", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-20T15:37:30.892Z", "location_count": 9, "location_summary": "Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04759781" } ] }